The article discusses the complex interactions between cancer cells and the bone microenvironment, which play a critical role in the development and progression of bone metastases. Cancer cells can alter the bone microenvironment to promote their growth and invasion, leading to severe complications such as bone fractures, pain, hypercalcaemia, and nerve compression. Bone metastases are common in cancers like breast and prostate, and their incidence is increasing due to improved control of other cancer sites. The bone microenvironment involves osteoclasts and osteoblasts, which regulate bone resorption and formation, and cancer cells can recruit and modulate various cell types, including platelets, immune cells, and nerve cells, to support their growth. The bone marrow also serves as a reservoir for dormant cancer cells that can later develop into metastases. Drugs targeting osteoclastogenesis, such as bisphosphonates and RANKL antibodies, are currently used to treat bone metastases, but they are not always effective. Understanding the basic biology of bone remodelling, haematopoiesis, and the bone microenvironment has led to new therapeutic targets for preventing and treating bone metastases. The article highlights the role of various factors, including WNT signalling, TGFβ, and integrins, in promoting bone metastases. It also discusses the importance of the pre-metastatic niche, where cancer cells prepare the bone microenvironment for metastasis, and the role of homing mechanisms in cancer cell colonization. The article also explores the role of various cell types, including osteoblasts, osteoclasts, immune cells, and platelets, in the bone metastasis process. It discusses the effects of bone resorption on tumour growth, the role of bone matrix proteins in tumour progression, and the potential of targeting bone metastases through various therapeutic strategies, including anti-angiogenic therapies, targeting osteoclasts, and targeting TGFβ. The article also addresses the challenges in treating cancer-associated bone pain and the need for better animal models to study bone metastasis. Overall, the article emphasizes the importance of understanding the bone microenvironment in the development of effective therapies for bone metastases.The article discusses the complex interactions between cancer cells and the bone microenvironment, which play a critical role in the development and progression of bone metastases. Cancer cells can alter the bone microenvironment to promote their growth and invasion, leading to severe complications such as bone fractures, pain, hypercalcaemia, and nerve compression. Bone metastases are common in cancers like breast and prostate, and their incidence is increasing due to improved control of other cancer sites. The bone microenvironment involves osteoclasts and osteoblasts, which regulate bone resorption and formation, and cancer cells can recruit and modulate various cell types, including platelets, immune cells, and nerve cells, to support their growth. The bone marrow also serves as a reservoir for dormant cancer cells that can later develop into metastases. Drugs targeting osteoclastogenesis, such as bisphosphonates and RANKL antibodies, are currently used to treat bone metastases, but they are not always effective. Understanding the basic biology of bone remodelling, haematopoiesis, and the bone microenvironment has led to new therapeutic targets for preventing and treating bone metastases. The article highlights the role of various factors, including WNT signalling, TGFβ, and integrins, in promoting bone metastases. It also discusses the importance of the pre-metastatic niche, where cancer cells prepare the bone microenvironment for metastasis, and the role of homing mechanisms in cancer cell colonization. The article also explores the role of various cell types, including osteoblasts, osteoclasts, immune cells, and platelets, in the bone metastasis process. It discusses the effects of bone resorption on tumour growth, the role of bone matrix proteins in tumour progression, and the potential of targeting bone metastases through various therapeutic strategies, including anti-angiogenic therapies, targeting osteoclasts, and targeting TGFβ. The article also addresses the challenges in treating cancer-associated bone pain and the need for better animal models to study bone metastasis. Overall, the article emphasizes the importance of understanding the bone microenvironment in the development of effective therapies for bone metastases.